Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 October 2010

A new drug form of blood coagulation factor IX: Red blood cell-entrapped factor IX

Elena Ivanovna SinauridzeABCDEF, Tatyana Alekseevna VuimoBF, Elena Viktorovna KulikovaB, Igor Igorevich ShmyrevB, Fazoil Inoyatovich AtaullakhanovAG

Med Sci Monit 2010; 16(10): PI19-26 :: ID: 881179

Abstract

Background: Deficiency of factor IX causes hemophilia B, and primary treatment for hemophilia B is based on recurrent infusions of deficient factor IX. Frequent infusions of foreign protein diminish patients’ quality of life, and increase the risk of development of immune reaction. We entrapped factor IX into erythrocytes-carriers (pharmacocytes) to prolong the drug’s circulation life time, and to prevent immune response to the drug.
Material/Methods: Factor IX was biotynilated by standard method and then loaded aseptically into volunteers’ erythrocytes with our gentle procedure of stepwise dialysis. The comparison of pharmacokinetics for free and autologous erythrocytes-entrapped biotinylated factor IX (FIXbiot) was done. Concentrations of factor IXbiot in plasma and lysates of erythrocytes were quantitatively assessed with a sandwich ELISA.
Results: Stepwise dialysis method allowed stable loading of factor IXbiot into erythrocytes. Elimination of the loaded erythrocytes followed the first-order kinetics. The mean half-time of elimination for free FIXbiot was 8.8±5.6 hours, and for RBC-entrapped factor IXbiot 73.9±16.0 hours. Elimination of FIXbiot from plasma did not follow the first order kinetics because this factor concentration depended not only on the rate of its elimination, but also on the rate of factor appearance in plasma as a result of pharmackocytes’ degradation. A rough estimate of the feasibility of the approach was done.
Conclusions: The life time of the erythrocyte-based form of FIXbiot in the circulation is significantly (5–10 times) prolonged compared with its free form, suggesting that this form has potential clinical applications.

Keywords: Kinetics, Hemophilia B - therapy, Feasibility Studies, Factor IX - therapeutic use, Erythrocytes, Drug Carriers, Biotinylation, Technology, Pharmaceutical, young adult

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750